Skeletal muscle mass in relation to 10 year cardiovascular disease incidence among middle aged and older adults: the ATTICA study by Tyrovolas, Stefanos et al.
26 Tyrovolas S, et al. J Epidemiol Community Health 2020;74:26–31. doi:10.1136/jech-2019-212268
Research report
Skeletal muscle mass in relation to 10 year 
cardiovascular disease incidence among middle aged 
and older adults: the ATTICA study
Stefanos Tyrovolas,1,2,3 Demosthenes Panagiotakos  ,3,4 Ekavi Georgousopoulou,3,4,5 
Christina Chrysohoou,6 Dimitrios Tousoulis,6 Josep Maria Haro,1,2,7 Christos Pitsavos6
To cite: Tyrovolas S, 
Panagiotakos D, 
Georgousopoulou E, et al. J 
Epidemiol Community Health 
2020;74:26–31.
1Parc Sanitari Sant Joan de Déu, 
Fundació Sant Joan de Déu, Dr 
Antoni Pujades, 42, 08830, Sant 
Boi de Llobregat, Barcelona, 
Spain
2Instituto de Salud Carlos 
III, Centro de Investigación 
Biomédica en Red de Salud 
Mental, CIBERSAM, Monforte de 
Lemos 3-5. Pabellón 11, 28029, 
Madrid, Spain
3Department of Science 
of Dietetics and Nutrition, 
School of Health Science and 
Education, Harokopio University, 
Athens, Greece
4Department of Nutrition and 
Dietetics, Faculty of Health, 
University of Canberra, 
Canberra, Australian Capital 
Territory, Australia
5Medical School, The Australian 
National University, Canberra, 
Australian Capital Territory, 
Australia
6First Cardiology Clinic, School 
of Medicine, University of 
Athens, Athens, Greece
7Department of Medicine, 
Universidad de Barcelona, 
Barcelona, Spain
Correspondence to
Dr Stefanos Tyrovolas, Parc 
Sanitari Sant Joan de Déu, 
Fundació Sant Joan de Déu, 
CIBERSAM,Dr. Antoni Pujadas, 
42, 08830 – Sant Boi de 
Llobregat, Barcelona, Spain;  
 s. tyrovolas@ pssjd. org
Received 12 February 2019
Revised 6 August 2019
Accepted 16 September 2019
Published Online First 
11 November 2019
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
AbsTrACT
background Skeletal muscle mass (SMM) is inversely 
associated with cardiometabolic health and the ageing 
process. The aim of the present work was to evaluate 
the relation between SMM and 10 year cardiovascular 
disease (CVD) incidence, among CVD- free adults 45+ 
years old.
Methods ATTICA is a prospective, population- based 
study that recruited 3042 adults without pre- existing 
CVD from the Greek general population (Caucasians; 
age ≥18 years; 1514 men). The 10 year study follow- up 
(2011–2012) captured the fatal/non- fatal CVD incidence 
in 2020 participants (50% men). The working sample 
consisted of 1019 participants, 45+ years old (men: 
n=534; women: n=485). A skeletal muscle mass index 
(SMI) was created to reflect SMM, using appendicular 
skeletal muscle mass (ASM) standardised by body mass 
index (BMI). ASM and SMI were calculated with specific 
indirect population formulas.
results The 10 year CVD incidence increased 
significantly across the baseline SMI tertiles (p<0.001). 
Baseline SMM showed a significant inverse association 
with the 10 year CVD incidence (HR 0.06, 95% CI 0.005 
to 0.78), even after adjusting for various confounders. 
Additionally, participants in the highest SMM tertile had 
81% (95% CI 0.04 to 0.85) lower risk for a CVD event 
as compared with those in the lowest SMM tertile.
Conclusions The presented findings support the 
importance of SMM evaluation in the prediction of 
long- term CVD risk among adults 45+ years old without 
pre- existing CVD. Preservation of SMM may contribute to 
CVD health.
InTroduCTIon
The global population is ageing at an unprecedented 
speed, especially in Europe. As a concept, ageing 
is considered a continuous process starting from 
birth and is accompanied by various physiological 
changes and a number of comorbidities1 2 that affect 
health and quality of life.3 4 Skeletal muscle mass 
(SMM)4 alterations are among these physiological 
changes.
SMM tissue decline, as a part of these physiolog-
ical changes, starts in middle age (or even earlier, 
in the 30s) and progresses in more advanced age.5 
It has been shown that SMM declines with a rate 
of more than 3% per decade starting from the age 
of 30+.6 Half of the human body's mass is actually 
SMM and it has an active role in numerous meta-
bolic pathways.5 7 SMM decline is related, among 
others, to various disability patterns, poor mental 
health and increased mortality.5 7 8 In addition, well 
documented studies have shown that SMM alter-
ations are related to cardiovascular health,9 10 even 
different muscle morphology.11 Recently, Srikan-
than et al12 reported the importance of muscle 
tissue in relation to cardiovascular disease (CVD) 
and total mortality in stable CVD patients.
It is well known that CVD is the major cause of 
mortality and morbidity in middle aged and older 
populations; specifically, in Greece, among those 
aged 50 to 70 years CVDs were related to more 
than 7295 disability- adjusted life years (DALYs) 
per 100 000 in 2017 (https:// vizhub. healthdata. 
org/ gbd- compare/). Moreover, although Greece is 
considered to be a country with a high life expec-
tancy, recent studies report an increase in the 
incidence of non- fatal CVD.13 Although various 
classical factors, such as unhealthy nutrition, 
excess body weight, smoking, physical inactivity, 
psychological disorders and low socioeconomic 
status, have long been considered among the major 
determinants for CVD development in middle aged 
people,13 the causal CVD pathway is still compli-
cated. Moreover, due to the population’s increased 
longevity, new factors have arisen (eg, muscle tissue 
loss, multimorbidity, etc), making CVD prevention 
even more complex.
Greece has a CVD risk profile that is similar to 
the other Mediterranean countries (Spain, France, 
Italy, Portugal, etc) and, despite the pronounced 
CVD and musculoskeletal disorders epidemic in 
these areas,13 14 there are no epidemiological data 
on SMM and CVD risk. To the best of our knowl-
edge, there have been limited studies evaluating the 
effect of SMM on CVD risk among only patients 
with stable CVD,12 but none among CVD- free 
populations. Given the complexity of the CVD 
“web of causation” implicating classical and new 
factors, the association of SMM with cardiometa-
bolic health and the ageing process, and the lack of 
data among Mediterranean (and other European) 
CVD- free populations, the aim of the present work 
was to evaluate the relation between SMM and 
10 year CVD incidence in the ATTICA study cohort 
among adults 45+ years old without previous CVD. 
Since evidence is emerging that targeted interven-
tion programmes can prevent muscle tissue alter-
ations, this study could provide useful information 
for effective, non- pharmacological CVD health 
promotion and planning.
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In brief, ATTICA is a prospective, population- based, cohort 
study performed in the Athens metropolitan region of Attica 
(Greece). The study recruited 3042 non- institutionalised adults 
(Caucasians; women/men: 1528/1514; 18+ years old) without 
previous CVD, out of a total of 4053 individuals who initially 
asked to participate (no differences as regards age and gender 
were observed between the individuals who asked to participate 
and those finally
recruited). Of the 3042 participants, 1544 (50.8%) were 45+ 
years old. The enrolment of the participants was carried out 
during 2001–2002, and after that two follow- up waves followed 
5 (in 2006) and 10 years (in 2012) later. Random, multistage 
sampling based on the age and gender distribution of the refer-
ence population, as defined by the Hellenic National Statistical 
Service Census Survey of 2001, was applied. Sampling proce-
dures anticipated enrolling only one participant per household, 
while institutionalised individuals were excluded from partici-
pating in the study. All participants underwent detailed baseline 
assessments which included medical history, physical examina-
tion and blood sampling for biochemical measurements. Baseline 
CVD was excluded in all participants by the study physicians. 
The ATTICA study was approved by our Institutional Ethics 
Committee (ID001/2002) and conformed to the ethical guide-
lines of the 1975 Declaration of Helsinki, with all participants 
providing written informed consent. The ATTICA methodology 
is described in detail elsewhere.15
baseline study assessments
Sociodemographic, bioclinical and lifestyle measurements
Comprehensive baseline data were collected, including demo-
graphic details (eg, age, gender and years of education), 
personal/family history of cardiometabolic disease (eg, hyperten-
sion, diabetes, hypercholesterolaemia and CVD), and informa-
tion about dietary and other lifestyle habits (eg, physical activity 
and smoking in pack years), as described previously.15 Briefly, 
all participants underwent a detailed baseline dietary evaluation 
through the EPIC- Greek questionnaire,16 which is a validated 
semi- quantitative food- frequency questionnaire that was kindly 
provided by the Unit of Nutrition of the Athens Medical School. 
Moreover, the MedDietScore was used to assess the adherence 
to the Mediterranean diet.17 Physical activity levels of each 
participant were also assessed at baseline using the International 
Physical Activity Questionnaire (IPAQ).18
At baseline, morning (8–10 am) fasting blood samples were 
obtained from all participants after overnight fasting (10–12 hours 
without food/alcohol intake, except for water). Triglyceride, total 
cholesterol and high- density lipoprotein cholesterol levels were 
measured by a standard chromatographic enzymatic method. 
Low- density lipoprotein cholesterol was calculated using the 
Friedewald formula.19 Hypercholesterolaemia was defined as 
total cholesterol >200 mg/dL or treatment with lipid- lowering 
drug(s). Moreover, subjects with fasting blood glucose >125 mg/
dL or on antidiabetic treatment were classified as having 
diabetes. Selected circulating pro- inflammatory biomarkers were 
also measured, namely high sensitivity C- reactive protein (CRP), 
as well as tumour necrosis factor α (TNFα) and interleukin-6 
(IL-6), following the specific protocols.20 Furthermore, resting 
arterial blood pressure (average of three recordings in the sitting 
position) was also measured at baseline, and individuals exhib-
iting an average blood pressure ≥140/90 mmHg or taking anti-
hypertensive medication(s) were categorised as hypertensive.
Skeletal muscle mass definition and calculation
Standardised measurements of anthropometric parameters were 
performed by trained study researchers at baseline, including 
body weight and height as well as waist circumference and 
hip circumference, in order to calculate the body mass index 
(BMI: body weight in kilograms divided by the height in metres 
squared; kg/m2). Individuals with BMI values >29.9 kg/m2 were 
grouped as obese. SMM was calculated throughout the appen-
dicular skeletal muscle mass (ASM) only for the Caucasian 
population, based on the equation proposed by Lee et al.21 This 
indicator was further adjusted by BMI to create a skeletal muscle 
mass index (SMI) as the proportion of ASM/BMI.22 In addition, 
SMI tertiles were created with the first tertile defining the low 
muscle mass.
CVD incidence at the 10 year follow-up (2002-2012)
The 10 year follow- up was conducted during 2011–2012 (median 
follow- up period: 8.41 years), as previously described.13 Briefly, 
2583 of the 3042 initial participants were re- assessed during the 
10 year follow- up (participation rate 85%). No differences were 
observed for age and gender distributions, as compared with 
the total sample (baseline age (mean±SD): 45±14 and 46±14 
years for women and men, respectively; of these 1370 (53%) 
were 45+ years old). However, of those who participated in 
the follow- up, accurate data regarding the development of CVD 
(and exact date) were obtained from 2020 participants; 1019 
of them were over 45 years old (with mean age of 56±9 years, 
men n=534 and women n=485), and comprised the working 
sample of this work. The definition of the investigated outcomes 
was based on the International Classification of Diseases, 10th 
version (ICD-10). In particular, information about the health 
status of the participants concerned development of: (a) myocar-
dial infarction, angina pectoris, other identified forms of isch-
aemia (ICD-9 coding (or 10th edition) 410–414.9, 427.2, 427.6 
(I20- I25)), and coronary revascularisation (414.01) (ie, coronary 
artery bypass surgery and percutaneous coronary intervention); 
(b) heart failure of different types (400.0–404.9, 427.0–427.5, 
427.9, 428.- (I50.2-)), and chronic arrhythmias (I49.-); (c) devel-
opment of stroke (430–438 (I63.-)) (ie, cases (a) to (c) defined 
CVD event); as well as (d) development of hypertension, hyper-
cholesterolaemia and diabetes (see below for diagnosis). As 
regards individuals who might have first suffered from a stroke 
and then had coronary heart disease (CHD), it was a priori 
decided that the first outcome should be considered as the end- 
point, but that the consequent event should also be recorded for 
further testing of competing risks (however, there were no such 
cases in the sample). For those participants who died during the 
follow- up, relevant information was retrieved from their rela-
tives and from the death certificates.13
statistical analysis
Normally distributed continuous variables are presented as 
mean±SD values, and categorical variables as frequencies. 
Normality was tested using the Shapiro- Wilk criterion; the non- 
normally distributed variables are presented as median and first 
and third tertile. Crude, non- fatal and fatal incidence rates of 
combined CVD (ie, cases (a) to (c) as described above) were 
calculated as the ratio of new cases to the number of partici-
pants at the 10 year follow- up. Associations between categor-
ical variables were tested by the χ2 test, whereas associations 
between continuous variables were tested by the Pearson’s r or 
Spearman’s ρ coefficients for normally distributed and skewed 
variables, respectively. Continuous variables were tested for 
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Table 1 Cardiovascular disease (CVD) cases during the ATTICA study 10 year follow- up and key baseline characteristics of the participants 45+ 
years old when categorised by baseline muscle mass tissue (SMI) tertiles (n=1019)








CVD during 10 year follow- up, n (% yes) 108 (31.7%) 117 (34.0%) 47 (14.0%)* <0.001
Baseline characteristics
  Age (years) 57.1±9.2 57.3±9.4 52.2±6.3* <0.001
  Gender (% male) 7 (02.0%) 299 (87.0%)* 335 (100.0%)* <0.001
  Smoking (% yes) 136 (40%) 227 (66%)* 235 (70.0%)* <0.001
  Physical activity (% physically active) 129 (38.0%) 138 (40.0%) 151 (45.0%) 0.07
  MedDietScore (range 0–55) 24.0±6.0 22.2±6.1* 24.1±4.0 <0.001
  Education (years at school) 10.1±4.1 10.2±4.1 13.3±4.0* <0.001
  SES (low/middle vs high) 58 (17.3%) 62 (18.0%) 151 (44.5%)* <0.001
  Obesity (% yes) 82 (23.8%) 110 (32.5%) 34 (10.8%)* <0.001
  Hypertension (% yes) 139 (41.0%) 169 (49.0%)* 134 (40.1%) 0.007
  Diabetes mellitus (% yes) 41 (12.0%) 55 (16.0%) 27 (08.0%)* 0.001
  Hypercholesterolaemia (% yes) 187 (55.2%) 172 (49.6%) 184 (52.0%) 0.15
Continuous variables are presented as mean±SD, and categorical as counts and relative frequencies (percentages). P values refer to the comparisons using χ2 test or t- test for the categorical 
and continuous variables, respectively; values for the between SMI group comparisons (vs first tertile) were corrected using the Bonferroni rule.
*p<0.05.
ASM, appendicular skeletal muscle mass; BMI, body mass index; MedDietScore, adherence to the Mediterranean diet; SES, socioeconomic status; SMI, skeletal muscle mass index.
normality via P- P plots. For normally distributed variables, 
comparisons of means between participants who developed 
CVD and those who remained CVD- free were performed by the 
Student’s t- test, after controlling for equality of variances by the 
Levene’s test. For continuous variables without normal distri-
bution, comparisons were performed by the non- parametric 
Mann- Whitney U- test. Cox proportional hazards models were 
used to estimate the hazard ratios (HR) and the corresponding 
95% confidence intervals (95% CI) of developing a CVD event 
during the study follow- up according to the baseline SMM 
(SMI) adjusted for other characteristics of participants (gender, 
education, socioeconomic level—model 1; smoking, physical 
activity, Mediterranean diet adherence—model 2; hypertension, 
diabetes, hypercholesterolaemia, obesity—model 3). Assumption 
of proportionality of hazards was graphically assessed; collin-
earity between covariates was tested through the correlation 
coefficients of the models’ parameters. Model’s goodness- of- fit 
was evaluated using −2logLikelihood (the lower the better). 
All p values are based on two- sided tests. Statistical analyses 
were performed using the Statistical Package for Social Sciences 
version 22 (SPSS Inc, Chicago, IL, USA).
resulTs
The fatal or non- fatal 10 year CVD incidence in the cohort was 
26.7%. Crude incidence (risk) of CVD, and various sociodemo-
graphic, lifestyle and bioclinical characteristics of the 45+ year 
old participants, by baseline SMI tertiles, are presented in table 1. 
The lowest 10 year CVD incidence was noted in the highest base-
line SMI tertile, compared with the lowest and middle ones (all 
p values <0.05). The prevalence of hypertension, diabetes and 
obesity was lower among the participants of the highest baseline 
muscle mass tertile (all p values <0.007). In addition, partici-
pants grouped in this tertile were younger, mostly men, smokers, 
more physically active, educated, had a high socioeconomic level 
and were more adherent to the Mediterranean diet (ie, higher 
MedDietScore) (all p values <0.07).
Table 2 presents the hazard ratios (HR and corresponding 
95% CI) of the survival models assessing the baseline SMI on 
the 10 year CVD incidence. Sociodemographic variables (gender, 
education, socioeconomic level—model 1), as well as certain 
lifestyle factors (smoking, physical activity, Mediterranean 
diet adherence—model 2) and clinical parameters (hyperten-
sion, diabetes, hypercholesterolaemia, obesity—model 3) were 
entered into the models. The analysis revealed that baseline SMI 
levels had a consistent and independent inverse association with 
10 year CVD incidence (HR 0.06, 95% CI 0.005 to 0.78) among 
45+ year old participants (table 2). Except for SMI, education 
level and adherence to the Mediterranean diet were also associ-
ated with lower 10 year CVD hazard (HR 0.91, 95% CI 0.84 to 
0.99, and HR 0.95, 95% CI 0.91 to 0.99, respectively), while 
the presence of hypertension (HR 1.64, 95% CI 1.05 to 2.57) 
and male gender (HR 3.7, 95% CI 1.32 to 10.5) were related to 
higher 10 year CVD hazard among individuals 45+ years old. 
Men had 6.1 times higher risk of incident CVD than women 
(95% CI 2.45 to 15.18). As regards other anthropometric char-
acteristics, increased BMI was associated with higher CVD 
hazard (HR 1.34, 95% CI 1.001 to 1.07) after adjusting for the 
same group of covariates as with SMI, whereas waist circumfer-
ence (HR 1.002, 95% CI 0.98 to 1.02) as well as waist- to- hip 
ratio were not significantly associated with CVD hazard in the 
studied sample (HR 2.60, 95% CI 0.32 to 21.19).
Moreover, as expected, SMI values were inversely associated 
with IL-6 (age, sex adjusted b- coefficient (p value): −0.11±0.01 
(p≤0.001)), CRP (b- coefficient (p value): −0.37±0.002 
(p≤0.001)) and fibrinogen (b- coefficient (p value): −12.54±3.34 
(p<0.001)). However, further mediation analysis showed no 
influence of the aforementioned inflammatory markers on the 
SMM–CVD relationship (data not shown here). Moreover, 
when BMI was entered in the final model replacing SMI, the 
estimated model showed lower goodness- of- fit as compared 
with the one which included SMI (ie, higher −2logLikelihood as 
compared with model 3).
A variety of previous studies have shown a strong effect 
between gender and muscle mass loss on human health.1 2 6 
In line with previous studies, a significant interaction between 
gender and SMI was also observed in the present work (p for 
copyright.
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Table 2 Results from the applied Cox proportional hazard models evaluating the 10 year risk of developing a cardiovascular disease event 
(outcome) according to the baseline values of muscle mass, for the ATTICA participants 45+ years old
All participants
hazard ratios (hr)†, 95% CIs
Model 1 Model 2 Model 3
SMI (ASM/BMI) 0.03** (0.003 to 0.24) 0.05* (0.005 to 0.58) 0.06* (0.005 to 0.78)
Men vs women 6.10** (2.45 to 15.18) 4.10** (1.57 to 10.71) 3.70* (1.32 to 10.53)
Education (years at school) 0.92* (0.85 to 0.99) 0.92 (0.85 to 1.00) 0.91* (0.84 to 0.99)
SES (low/middle vs high) 1.32 (0.65 to 2.70) 1.33 (0.65 to 2.72) 1.55 (0.73 to 3.29)
MedDietScore (range 0–55) – 0.95* (0.92 to 0.99) 0.95* (0.91 to 0.99)
Smoking ever (yes vs no) – 1.14 (0.73 to 1.78) 1.23 (0.77 to 1.98)
Physically active (yes vs no) – 0.94 (0.61 to 1.43) 0.93 (0.59 to 1.44)
Obesity (yes vs no) – – 0.66 (0.38 to 1.15)
Hypertension (yes vs no) – – 1.64* (1.05 to 2.6)
Diabetes mellitus (yes vs no) – – 1.64 (0.87 to 3.09)
Hypercholesterolaemia (yes vs no) – – 1.15 (0.73 to 1.80)
*p<0.05 **p<0.001.
†Hazard ratios derived from semi- parametric Cox proportional hazards models.
ASM, appendicular skeletal muscle mass; BMI, body mass index; MedDietScore, adherence to the Mediterranean diet; SES, socioeconomic status; SMI, skeletal muscle mass index.
Table 3 Results from Cox proportional hazards model that evaluated 
the 10 year cardiovascular disease (CVD) risk by baseline muscle mass 
tertile, in the ATTICA study participants 45+ years old.
hr 95% CI
Men vs women 3.83 0.97 to 15.2
Education (years at school) 0.91* 0.84 to 0.99
SES (low/middle vs high) 1.67 0.78 to 3.56
MedDietScore (range 0–55) 0.95** 0.91 to 0.98
Smoking ever (yes vs no) 1.26 0.79 to 2.02
Physically active (yes vs no) 0.92 0.59 to 1.44
Obesity (yes vs no) 0.66 0.38 to 1.14
Hypertension (yes vs no) 1.69* 1.08 to 2.65
Diabetes mellitus (yes vs no) 1.55 0.82 to 2.94
Hypercholesterolaemia (yes vs no) 1.16 0.74 to 1.83
SMI (ASM/BMI)
  First tertile Reference
  Second tertile 0.46 0.11 to 1.81
  Third tertile 0.19* 0.04 to 0.85
*p<0.05 **p<0.001.
ASM, appendicular skeletal muscle mass; BMI, body mass index; MedDietScore, adherence 
to the Mediterranean diet; SES, socioeconomic status; SMI, skeletal muscle mass index.
interaction <0.001). Thus, to further test the role of gender, the 
previous analysis was stratified in males and females. The SMI 
levels were inversely associated with the 10 year CVD incidence 
in 45+ year old males (HR 0.03, 95% CI 0.001 to 0.744), but 
not in females (HR 0.18, 95% CI 0.002 to 17.13).
In order to further explore the potential dose- dependent 
association of SMM with CVD incidence, further analysis was 
applied by SMI tertiles. Table 3 presents the hazard ratios of 
the regression model assessing the 10 year CVD risk by baseline 
SMI tertiles. Based on the applied analysis, only individuals in 
the highest SMI tertile as compared with those in the lowest had 
a significantly lower hazard for developing a CVD event (HR 
0.19, 95% CI 0.04 to 0.85).
dIsCussIon
Although SMM has an important cardiometabolic effect,10 23 until 
now there have been no data from Europe and the Mediterranean 
basin investigating the role of muscle tissue on CVD risk among 
CVD- free populations. The present study reports an inverse 
association between SMM (as reflected by SMI) preservation and 
the 10 year CVD incidence in a large community- based cohort of 
CVD- free adults 45+ years old. Notably, this relation was inde-
pendent of the dietary habits, socioeconomic level and multiple 
well- established CVD risk factors such as smoking habits, hyper-
tension, hypercholesterolaemia and diabetes. Further analysis by 
SMM subgroups (tertiles) shows that only the subgroup of the 
highest SMM had the lowest 10 year CVD risk. To the best of 
our knowledge, this is the first study to evaluate the association 
between SMM and CVD risk among adults without previous 
CVD. These results point to the importance of SMM preserva-
tion in relation to CVD risk and the public health actions that 
need to be taken to improve CVD health in middle aged and 
older populations.
SMM has been shown to be related to various health outcomes, 
not only in older adults but also among middle aged populations.2 
SMM has been shown to be inversely related to CVD health and 
outcomes such as cardiometabolic health, insulin secretion and 
resistance, metabolic syndrome and diabetes.9 10 23 24 These data 
are in line with the applied unadjusted analysis where the high 
baseline SMM participant’s group had a lower prevalence of CVD 
risk factors such as obesity, diabetes and hypertension. Muscle 
tissue has been reported to be associated with endocrine declines 
(ie, testosterone and growth hormone levels) in parallel with the 
body’s ongoing ageing process, explaining the initial interaction 
analysis between age and SMM. Despite increasing evidence of 
the correlation between SMM and CVD health among middle 
aged and older populations, so far only studies involving CVD 
or CHD patients have reported the association between muscle 
tissue, obesity, CVD risk and all- cause mortality risk.12 25 This has 
been noted as the ‘obesity- lean’ paradox, describing the effect of 
body composition changes among CVD patients, which may not 
apply in our analysis where the population was initially CVD- 
free because of the diverse pathophysiology (ie, cardiorespiratory 
fitness).26 SMM is known for its major role in the glucose pathway 
in the human body, highlighting its metabolic significance.24 Taking 
into account the well- known association of insulin resistance with 
CVD,27 it is reasonable to conclude that the metabolic function 
of SMM has an impact on CVD risk. The aforementioned major 
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What is already known on this subject
 ► Skeletal muscle mass declines with increasing of age. 
Alterations in skeletal muscle mass are related to various 
disability patterns, mental diseases, cardiovascular health and 
mortality.
What this study adds
 ► Limited studies have evaluated the effect of skeletal muscle 
mass on cardiovascular risk only in patients with stable 
cardiovascular disease, but there have been no studies 
involving cardiovascular disease- free populations, until now.
 ► The findings of this study support the importance of skeletal 
muscle mass evaluation in the prediction of long- term 
cardiovascular disease risk among middle aged and older 
adults without pre- existing cardiovascular disease.
metabolic pathway could possibly explain the reported association 
between SMM and the 10 year CVD incidence.
To further explore the effect of SMM preservation on 10 year 
CVD incidence, SMM (as reflected by SMI) tertile analysis was 
applied. It was considered that only the highest tertile of SMM 
conferred protection against CVD risk as compared with the lowest 
tertile of SMM. In addition, inflammatory28 29 and metabolic 
interrelated pathways1 could possibly explain the reported asso-
ciation between SMM preservation and 10 year CVD incidence. 
Specifically, inflammation markers such as TNFα, IL-6 and CRP 
have been inversely related to skeletal muscle tissue,29 30 as a part 
of complex physiological pathways. To test the aforementioned, 
a multi- adjusted regression model between selected biomarkers 
(IL-6, CRP and fibrinogen) and the SMI was applied (having the 
same confounders as those in table 3), without altering the already 
observed association between SMI and CVD incidence.
Furthermore, previous cross- national studies have reported 
that male gender is related to higher skeletal muscle mass.2 
Based on that, we also analysed separately males and females 
and it was revealed that SMM influences the cardiometabolic 
risk of males but not of females. This association could be partly 
explained by the different nature of ageing (ie, endocrine, testos-
terone levels) among genders and its interrelation to the meta-
bolic- CVD pathway. In addition, the ‘gender paradox’ in healthy 
ageing (being female is related to a higher comorbidity burden)31 
could also explain the different gender effect of SMM in CVD 
health reported in our analysis.
Currently middle aged and older individuals in Europe and the 
Mediterranean basin are experiencing poor quality of life due to 
musculoskeletal disorders in parallel with increased CVD risk.14 
Progressive SMM loss, in addition to causing declines in gait speed 
and muscle strength, could lead to sarcopenia, even in the 50+ year 
old population,2 a condition related to multimorbidity, disability 
and increased healthcare expenses.32 These associations—combined 
with the fact that the Greek population, like other populations in the 
Mediterranean area, is ageing and the CVD burden is increasing—
raise major concerns about the need for early non- pharmacological 
measures in order to promote CVD health. Specific nutrition and 
physical strategies are the factors that could be possible targets for 
community interventions and health education campaigns in order 
to avoid the decline in lean mass. Recent studies have shown that 
health promotion programmes and interventions that include exer-
cise strategies (ie, periodic physical activity, resistance training) and 
high protein intake under a specific plan33 could help to preserve 
muscle mass in ageing.34 35 Stakeholders in Greece could consider 
the muscle mass decline among the CVD risk factors for the coun-
try's middle aged and older population. Muscle mass preservation 
through resistance exercise and specific dietary habits within the 
Mediterranean diet could serve as cost- effective actions for CVD 
prevention in the community of middle aged and older adults.36 Of 
course, future studies should evaluate physical activity, nutritional 
and other lifestyle interventions to attain a beneficial SMM and 
potentially decrease long- term CVD risk.
strengths and limitations
The present study has major strengths. It is the first study to eval-
uate the association between SMM (as reflected by SMI), and the 
10 year CVD incidence of a large sample of CVD- free adults aged 
45+ years. The use of a CVD- free population is really important, 
since cardiac patients have a different physiology, different lifestyle 
habits, functional limitations and disabilities that may mediate 
the investigated association between SMM and CVD incidence. 
In addition, this research work shows the role of muscle mass as 
a potential determinant of CVD health among middle aged and 
older subjects. This finding could serve as benchmark in the devel-
opment of CVD prevention programmes in ageing communities.
Among the study’s limitations, it should be noted that the base-
line/entry study examination was conducted once and could be 
susceptible to a certain degree of measurement error. However, 
the applied methodology is similar to well- known longitudinal, 
CVD- outcome epidemiological studies, and followed stan-
dardised and validated protocols/methods regarding the data 
collection. Moreover, the enrolment of participants only from 
a specific area, and without any history of chronic disease, may 
limit the generalisation of the findings to other populations due 
to selection bias. Additionally, in studies like the present one the 
correspondence between CVD- specific hazard and cumulative 
incidence is usually lost.37 This has a very important implication; 
specifically, the way in which covariates are associated with the 
hazards may not coincide with the way these covariates are asso-
ciated with the cumulative incidence. Thus, the results should 
be interpreted with caution. Regarding the current analysis, the 
CVD rate was not constant across time and, thus, the implication 
of cumulative incidence could be misleading. The assessment of 
SMM was based on population equations that may under- or 
overestimate the actual SMM rates. However, it is well known 
that these formulas are validated and present good agreement 
with the classical method of dual- energy X- ray absorptiom-
etry (DXA) measurement.21 38 Epidemiologic studies in diverse 
settings have used these formulas (ASM, ASM/BMI) for the 
calculation of SMM.2 Also, despite the fact that assessments of 
functioning, such as grip strength and gait speed, are related to 
muscle mass and older adult’s health, the ATTICA study did 
not include such information. Furthermore, not including in 
the analysis additional measurements of obesity (such as waist 
circumference or other effects of body fat) may also limit our 
findings on the kind of association between BMI, waist circum-
ference or body fat and CVD incidence. Finally, the fact that 
the present analysis was based only on baseline SMI values is 
an additional limitation, especially for capturing the effect of 
decline in SMI over time on CVD incidence.
ConClusIon
The present work evaluated the role of SMM on CVD inci-
dence in 45+ year old adults without pre- existing CVD. It is of 
major interest nowadays to study the SMM transition in order 
to better understand its role on CVD outcomes. Throughout 
this study, the importance of SMM preservation to prevent 
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long- term CVD risk among the middle aged/older population 
has been highlighted. The prevention of SMM decline, which is 
becoming increasingly prevalent among middle aged and older 
populations, may constitute an effective means of promoting 
CVD health.
Acknowledgements The authors would like to thank the ATTICA study group of 
investigators: Yannis Skoumas, Natasa Katinioti, Labros Papadimitriou, Constantina 
Masoura, Spiros Vellas, Yannis Lentzas, Manolis Kambaxis, Konstanitna Paliou, 
Vassiliki Metaxa, Agathi Ntzouvani, Dimitris Mpougatas, Nikolaos Skourlis, Christina 
Papanikolaou, Aikaterini Kalogeropoulou, Evangelia Pitaraki, Alexandros Laskaris, 
Mihail Hatzigeorgiou, Athanasios Grekas, and Eleni Kokkou for assistance in the 
initial physical examination and/or the follow- up evaluation; Efi Tsetsekou for her 
assistance in psychological evaluation and follow- up evaluation, as well as the 
laboratory team: Carmen Vassiliadou and George Dedousis (genetic analysis), Marina 
Toutouza- Giotsa, Constantina Tselika and Sia Poulopoulou (biochemical analysis), 
and Maria Toutouza for the database management. We would also like to thank all 
the participants of the ATTICA study.
Contributors Study design: ST and DBP. Data analysis: ST, DBP. Data interpretation: 
ST, DBP, ENG, CC, JMH, DT, CC, and CP. Drafting manuscript: ST and DBP. Revising 
manuscript content: ENG, CC, JMH, DT, CC, and CP. Approving final version of 
manuscript: All authors.
Funding The ATTICA study is supported by research grants from the Hellenic 
Cardiology Society (HCS2002) and the Hellenic Atherosclerosis Society (HAS2003). 
This work was supported by the Ageing Trajectories of Health: Longitudinal 
Opportunities and Synergies (ATHLOS) project, which has received funding from 
the European Union’s Horizon 2020 research and innovation program under grant 
agreement No 635316. Stefanos Tyrovolas’s work was supported by the Foundation 
for Education and European Culture (IPEP), the Sara Borrell postdoctoral program 
(reference no. CD15/00019 from the Instituto de Salud Carlos III (ISCIII - Spain) and 
the Fondos Europeo de Desarrollo Regional (FEDER).
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement Data are available upon reasonable request.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId id
Demosthenes Panagiotakos http:// orcid. org/ 0000- 0001- 8583- 153X
RefeRences
 1 Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. Int J 
Endocrinol 2013;2013:1–12.
 2 Tyrovolas S, Koyanagi A, Olaya B, et al. Factors associated with skeletal muscle mass, 
sarcopenia, and sarcopenic obesity in older adults: a multi- continent study. J Cachexia 
Sarcopenia Muscle 2016;7:312–21.
 3 Landi F, Cruz- Jentoft AJ, Liperoti R, et al. Sarcopenia and mortality risk in frail 
older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing 
2013;42:203–9.
 4 Liguori I, Russo G, Aran L, et al. Sarcopenia: assessment of disease burden and 
strategies to improve outcomes. Clin Interv Aging 2018;13:913–27.
 5 Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among 
the elderly in New Mexico. Am J Epidemiol 1998;147:755–63.
 6 Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr 
Metab Care 2004;7:405–10.
 7 Newman AB, Kupelian V, Visser M, et al. Strength, but not muscle mass, is associated 
with mortality in the health, aging and body composition study cohort. J Gerontol A 
Biol Sci Med Sci 2006;61:72–7.
 8 Hsu Y- H, Liang C- K, Chou M- Y, et al. Association of cognitive impairment, depressive 
symptoms and sarcopenia among healthy older men in the Veterans retirement 
community in southern Taiwan: a cross- sectional study. Geriatr Gerontol Int 
2014;14(Suppl 1):102–8.
 9 Shishikura K, Tanimoto K, Sakai S, et al. Association between skeletal muscle 
mass and insulin secretion in patients with type 2 diabetes mellitus. Endocr J 
2014;61:281–7.
 10 Kim Y, Han B- D, Han K, et al. Optimal cutoffs for low skeletal muscle mass related to 
cardiovascular risk in adults: the Korea National health and nutrition examination 
survey 2009–2010. Endocrine 2015;50:424–33.
 11 Andersen K, Lind L, Ingelsson E, et al. Skeletal muscle morphology and risk of 
cardiovascular disease in elderly men. Eur J Prev Cardiol 2015;22:231–9.
 12 Srikanthan P, Horwich TB, Tseng CH. Relation of muscle mass and fat mass to 
cardiovascular disease mortality. Am J Cardiol 2016;117:1355–60.
 13 Panagiotakos DB, Georgousopoulou EN, Pitsavos C, et al. Ten- year (2002–2012) 
cardiovascular disease incidence and all- cause mortality, in urban Greek population: 
the ATTICA study. Int J Cardiol 2015;180:178–84.
 14 Haro JM, Tyrovolas S, Garin N, et al. The burden of disease in Spain: results from the 
Global Burden of Disease Study 2010. BMC Med 2014;12:236.
 15 Pitsavos C, Panagiotakos DB, Chrysohoou C, et al. Epidemiology of cardiovascular risk 
factors in Greece: aims, design and baseline characteristics of the ATTICA study. BMC 
Public Health 2003;3:32.
 16 Katsouyanni Ket al. Reproducibility and relative validity of an extensive semi- 
quantitative food frequency questionnaire using dietary records and biochemical 
markers among Greek schoolteachers. Int J Epidemiol 1997;26(90001):118S–27.
 17 Panagiotakos DB, Pitsavos C, Stefanadis C. Dietary patterns: a Mediterranean diet 
score and its relation to clinical and biological markers of cardiovascular disease risk. 
Nutr Metab Cardiovasc Dis 2006;16:559–68.
 18 Papathanasiou G, Georgoudis G, Papandreou M, et al. Reliability measures of the 
short International Physical Activity Questionnaire (IPAQ) in Greek young adults. 
Hellenic J Cardiol 2009;50:283–94.
 19 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low- density 
lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin 
Chem 1972;18:499–502.
 20 Kyrou I, Panagiotakos DB, Kouli G- M, et al. Lipid accumulation product in relation 
to 10- year cardiovascular disease incidence in Caucasian adults: the ATTICA study. 
Atherosclerosis 2018;279:10–16.
 21 Lee RC, Wang Z, Heo M, et al. Total- body skeletal muscle mass: development 
and cross- validation of anthropometric prediction models. Am J Clin Nutr 
2000;72:796–803.
 22 Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study 
description, conference recommendations, and final estimates. J Gerontol A Biol Sci 
Med Sci 2014;69:547–58.
 23 Moon JH, Choo SR, Kim JS. Relationship between low muscle mass and metabolic 
syndrome in elderly people with normal body mass index. J Bone Metab 
2015;22:99–106.
 24 Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with 
insulin resistance and prediabetes. findings from the Third National Health and 
Nutrition Examination Survey. J Clin Endocrinol Metab 2011;96:2898–903.
 25 Wannamethee SG, Shaper AG, Whincup PH, et al. The obesity paradox in men with 
coronary heart disease and heart failure: the role of muscle mass and leptin. Int J 
Cardiol 2014;171:49–55.
 26 Lavie CJ, De Schutter A, Patel D, et al. Body composition and coronary heart disease 
mortality—an obesity or a lean paradox? Mayo Clin Proc 2011;86:857–64.
 27 Papakonstantinou E, Lambadiari V, Dimitriadis G, et al. Metabolic syndrome and 
cardiometabolic risk factors. Curr Vasc Pharmacol 2014;11:858–79.
 28 Costamagna D, Costelli P, Sampaolesi M, et al. Role of inflammation in muscle 
homeostasis and myogenesis. Mediators Inflamm 2015;2015:1–14.
 29 Wåhlin- Larsson B, Wilkinson DJ, Strandberg E, et al. Mechanistic links underlying 
the impact of C- reactive protein on muscle mass in elderly. Cell Physiol Biochem 
2017;44:267–78.
 30 Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis 
factor- alpha with muscle mass and muscle strength in elderly men and women: the 
health ABC study. J Gerontol A Biol Sci Med Sci 2002;57:M326–32.
 31 Tyrovolas S, Haro JM, Mariolis A, et al. Successful aging, dietary habits and health 
status of elderly individuals: a k- dimensional approach within the multi- national 
MEDIS study. Exp Gerontol 2014;60:57–63.
 32 Janssen I, Shepard DS, Katzmarzyk PT, et al. The healthcare costs of sarcopenia in the 
United States. J Am Geriatr Soc 2004;52:80–5.
 33 Oikawa SY, Holloway TM, Phillips SM. The impact of step reduction on muscle health 
in aging: protein and exercise as countermeasures. Front Nutr 2019;6.
 34 Freiberger E, Sieber C, Pfeifer K. Physical activity, exercise, and sarcopenia - future 
challenges. Wien Med Wochenschr 2011;161:416–25.
 35 Beavers KM, Ambrosius WT, Rejeski WJ, et al. Effect of exercise type during intentional 
weight loss on body composition in older adults with obesity. Obesity 2017;25:1823–9.
 36 Tyrovolas S, Haro J- M, Mariolis A, et al. Skeletal muscle mass and body fat in relation 
to successful ageing of older adults: the multi- national MEDIS study. Arch Gerontol 
Geriatr 2016;66:95–101.
 37 Andersen PK, Geskus RB, de Witte T, et al. Competing risks in epidemiology: 
possibilities and pitfalls. Int J Epidemiol 2012;41:861–70.
 38 Cawthon PM, Peters KW, Shardell MD, et al. Cutpoints for low appendicular lean 
mass that identify older adults with clinically significant weakness. J Gerontol A Biol 
Sci Med Sci 2014;69:567–75.
copyright.











ealth: first published as 10.1136/jech-2019-212268 on 11 N
ovem
ber 2019. D
ow
nloaded from
 
